Search results for "Sequencing"

showing 10 items of 1087 documents

Microbiological and safety evaluation of green table olives marketed in Italy

2011

The microbiological and safety conditions of green table olives sold on the Italian market were evaluated on 40 samples, 20 loose and 20 packed in containers, purchased at street markets and supermarkets. The olives were analyzed for microflora and food safety indices, and for aflatoxin B1 and ochratoxin A occurrence, and the results showed acceptable security. There was wide heterogeneity in the microflora, the numerical values being in relation to the olive type. The microbial population was dominated by the yeasts and lactic bacteria responsible for the fermentation process, and their numbers, together with the metabolic activity, led to conditions unfavorable for the development of path…

Ochratoxin AAflatoxineducation.field_of_studybusiness.industryTable olives Microbial contamination PCR sequencing Aflatoxin B1 Ochratoxin APopulationfood and beveragesSettore AGR/15 - Scienze E Tecnologie AlimentariBiologyFood safetySettore BIO/19 - Microbiologia GeneraleApplied Microbiology and BiotechnologyLactic acidFecal coliformchemistry.chemical_compoundSettore BIO/18 - GeneticachemistryFermentationFood scienceMycotoxineducationbusinessSettore AGR/16 - Microbiologia Agraria
researchProduct

A polyphasic approach to the identification of ochratoxin A-producing black Aspergillus isolates from vineyards in Sicily.

2008

Aspergillus strains belonging to section Nigri isolated during a two year survey in eight Sicilian vineyards located on the slopes of Mount Etna (Sicily, Italy) were analysed analyzed in order to characterize species responsible for ochratoxin A (OTA) contamination of grapes. The polyphasic approach permitted analysis of biodiversity of Aspergillus isolates in relation to their morphology, ochratoxigenicity and genetic variability. We assessed OTA production by A. carbonarius, A. niger, A. tubingensis and A. japonicus using an enzyme-linked immunosorbent assay. A. carbonarius isolates were the strongest OTA producers. A subset of 66 representative strains was selected for further DNA-based …

Ochratoxin AVeterinary medicineEnzyme-Linked Immunosorbent AssayFood ContaminationfAFLPMicrobiologylaw.inventionMicrobiologychemistry.chemical_compoundVineyard OTA A. carbonariusPCR identificationSpecies SpecificitylawDNA Ribosomal SpacerCluster AnalysisVitisGenetic variabilityDNA FungalOchratoxinAspergillus; Ochratoxin A; fAFLP; PCR identification; 16s rDNA sequencingPolymerase chain reactionPhylogenyAspergillusbiology16s rDNA sequencingAspergillus nigerOchratoxin AGeneral MedicineFungi imperfectiSequence Analysis DNAbiology.organism_classificationOchratoxinsRNA Ribosomal 5.8SAspergilluschemistryItalyAspergillus nigerRestriction fragment length polymorphismPolymorphism Restriction Fragment LengthFood ScienceInternational journal of food microbiology
researchProduct

Integrative bioinformatics and omics data source interoperability in the next-generation sequencing era-Editorial.

2021

With the advent of high-throughput and next-generation sequencing (NGS) technologies [1], huge amounts of ‘omics’ data (i.e. data from genomics, proteomics, pharmacogenomics, metagenomics, etc.) are continuously produced. Combining and integrating diverse omics data types is important in order to investigate the molecular machinery of complex diseases, with the hope for better disease prevention and treatment [2]. Experimental data repositories of omics data are publicly available, with the main aim of fostering the cooperation among research groups and laboratories all over the world. However, despite their openness, the effective integrated use of available public sources is hampered by t…

Omics dataIntegrative bioinformaticsSettore INF/01 - InformaticaComputer scienceInteroperabilityComputational BiologyHigh-Throughput Nucleotide SequencingMolecular BiologyData sciencedata integration omics data sources interoperabilityDNA sequencingInformation SystemsBriefings in bioinformatics
researchProduct

Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.

2021

Abstract Background The single‐arm DAWN trial (NCT01779791) of ibrutinib monotherapy in patients with relapsed/refractory follicular lymphoma (FL) showed an overall response rate (ORR) of 20.9% and a median response duration of 19.4 months. This biomarker analysis of the DAWN dataset sought to determine genetic classifiers for prediction of response to ibrutinib treatment. Methods Whole exome sequencing was performed on baseline tumor samples. Potential germline variants were excluded; a custom set of 1216 cancer‐related genes was examined. Responder‐ versus nonresponder‐associated variants were identified using Fisher's exact test. Classifiers with increasing numbers of genes were created …

OncologyCancer ResearchFollicular lymphomaBiochemistrychemistry.chemical_compoundGenetic signaturePiperidinesRecurrenceMedicineExomeLymphoma FollicularExome sequencingRC254-282Research ArticlesNeoplasms. Tumors. Oncology. Including cancer and carcinogensHematologyDNA-Binding ProteinsExact testOncologyIbrutinibRefractory Follicular LymphomaClin oncolResearch ArticleGenetic Markersmedicine.medical_specialtyImmunologyAntineoplastic AgentslymphomaBiologyGermline mutationInternal medicinePartial responseExome SequencingHumansRadiology Nuclear Medicine and imagingIn patientbusiness.industryAdeninegenetic variantsClinical Cancer ResearchbiomarkersCell Biologymedicine.diseasemutationsFANCAMutational analysisCARD Signaling Adaptor ProteinschemistryGuanylate CyclaseFamily medicineRelapsed refractoryMutationbusinessCancer medicine
researchProduct

Multimodal Deep Learning for Prognosis Prediction in Renal Cancer

2021

BackgroundClear-cell renal cell carcinoma (ccRCC) is common and associated with substantial mortality. TNM stage and histopathological grading have been the sole determinants of a patient’s prognosis for decades and there are few prognostic biomarkers used in clinical routine. Management of ccRCC involves multiple disciplines such as urology, radiology, oncology, and pathology and each of these specialties generates highly complex medical data. Here, artificial intelligence (AI) could prove extremely powerful to extract meaningful information to benefit patients.ObjectiveIn the study, we developed and evaluated a multimodal deep learning model (MMDLM) for prognosis prediction in ccRCC.Desig…

OncologyCancer ResearchPrognosis predictionmedicine.medical_specialtyrenal cancerDiseaseRenal cell carcinomaInternal medicinemedicineStage (cooking)Exome sequencingRC254-282Original Researchbusiness.industryDeep learningCancerdeep learningNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseartificial intelligenceradiologyOncologyCohortpathologyArtificial intelligenceprognosis predictionbusinessFrontiers in Oncology
researchProduct

Clinical utility of plasma-based digital next-generation sequencing (NGS) in patients with advance-stage lung adenocarcinomas with insufficient tumor…

2018

9101Background: Approximately 20 % of tumor biopsies from patients with advanced-stage lung adenocarcinomas yield insufficient tissue for successful molecular subtyping. In this study, we have anal...

OncologyCancer Researchmedicine.medical_specialtyLungbusiness.industryDNA sequencingSubtypingInsufficient Tissuemedicine.anatomical_structureOncologyInternal medicineMedicineIn patientStage (cooking)businessGenotypingJournal of Clinical Oncology
researchProduct

Abstract PD3-6: ConvertHER: Evolution of genomic alterations from primary to metastatic breast cancer

2015

Abstract Background: Changes in breast cancer receptor status over disease progression and treatment have been described to a point that could alter response to therapy. There is growing interest in delivering biomarker/genomically-based targeted therapies. We aimed to determine the concordance of genomic alterations between primary (P) and metastatic (M) breast cancer in a prospective collection study. Methods: Targeted capture and next-generation sequencing was performed on formalin-fixed paraffin-embedded (FFPE) samples, profiling 202 cancer relevant genes in 61 pairs (primary and corresponding recurrence/metastasis). Tumors were classified at baseline as [hormone receptor (HR)+/HER2-, H…

OncologyCancer Researchmedicine.medical_specialtyPathologybusiness.industryMAP3K1medicine.diseaseMetastatic breast cancerMetastasisExonBreast cancerOncologyInternal medicinemedicineMEN1skin and connective tissue diseasesbusinessExome sequencingTriple-negative breast cancerCancer Research
researchProduct

Strong founder effects in BRCA1 mutation carrier breast cancer patients from Latvia

1999

Germ-line mutations of the BRCA1 gene account for approximately half of the cases of hereditary breast/ovarian cancers. We have screened index patients from 15 breast cancer families and 8 sporadic breast cancer patients from Latvia for mutations in all coding exons of the BRCA1 gene, using combined Heteroduplex Analysis/SSCP followed by direct sequencing of the variants. BRCA1 germ-line mutations proved to be frequent in Latvian breast cancer patients, also in moderate-risk families and sporadic patients. Out of 23 cases a total of 8 patients (35%) exhibited three different mutations (5382insC, C61G, 4153delA). Interestingly, these three recurrent mutations accounted for all mutations in o…

OncologyGeneticsmedicine.medical_specialtyMutationDirect sequencingSingle-strand conformation polymorphismBiologymedicine.diseasemedicine.disease_causeExonBreast cancerInternal medicineGeneticsmedicineGenetics (clinical)Brca1 geneFounder effectHeteroduplexHuman Mutation
researchProduct

Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer

2019

Background The role of the BARD1 gene in breast cancer (BC) and ovarian cancer (OC) predisposition remains elusive, as published case-control investigations have revealed controversial results. We aimed to assess the role of deleterious BARD1 germline variants in BC/OC predisposition in a sample of 4920 BRCA1/2-negative female BC/OC index patients of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC). Methods A total of 4469 female index patients with BC, 451 index patients with OC, and 2767 geographically matched female control individuals were screened for loss-of-function (LoF) mutations and potentially damaging rare missense variants in BARD1. All patients met the …

OncologyGermline0302 clinical medicineLoss of Function MutationSurgical oncologyOdds RatioPrevalenceMissense mutation030212 general & internal medicineAge of Onset10. No inequalityExomeEarly onset breast cancerAged 80 and overOvarian NeoplasmsBARD1 GeneHigh-Throughput Nucleotide SequencingMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good health030220 oncology & carcinogenesisFemaleTechnology PlatformsResearch ArticleAdultmedicine.medical_specialtyAdolescentUbiquitin-Protein Ligases610Breast Neoplasmslcsh:RC254-282Young Adult03 medical and health sciencesGermline mutationBreast cancerOvarian cancerInternal medicinemedicineBARD1HumansGenetic Predisposition to DiseaseGermline mutationsGenetic Association StudiesGerm-Line MutationAgedbusiness.industryTumor Suppressor ProteinsOdds ratiomedicine.diseaseConfidence intervalBARD1; Early onset breast cancer; Germline mutations; Ovarian cancerOvarian cancerbusiness
researchProduct

Evaluation of a combined triple method to detect causative HPV in oral and oropharyngeal squamous cell carcinomas: p16 Immunohistochemistry, Consensu…

2012

Abstract Background Recent emerging evidences identify Human Papillomavirus (HPV) related Head and Neck squamous cell carcinomas (HN-SCCs) as a separate subgroup among Head and Neck Cancers with different epidemiology, histopathological characteristics, therapeutic response to chemo-radiation treatment and clinical outcome. However, there is not a worldwide consensus on the methods to be used in clinical practice. The endpoint of this study was to demonstrate the reliability of a triple method which combines evaluation of: 1. p16 protein expression by immunohistochemistry (p16-IHC); 2. HPV-DNA genotyping by consensus HPV-DNA PCR methods (Consensus PCR); and 3 viral integration into the host…

OncologyHuman papillomavirusHPVCancer Researchmedicine.medical_specialtyPathologyMethylation-Specific PCREpidemiologySettore MED/50 - Scienze Tecniche Mediche ApplicateBisulfite sequencingConsensus PCRIn situ hybridizationSettore MED/08 - Anatomia Patologicalcsh:RC254-282lcsh:Infectious and parasitic diseasesHPV-DNA; in situ hybridationSettore MED/28 - Malattie OdontostomatologicheInternal medicinemedicineDNA consensus PCRlcsh:RC109-216p16-IHCin situ hybridationGenotypingHN-SCCOPSCCbusiness.industryHead and neck cancerEpigeneticHPV-DNAHead and neck squamous cell carcinomalcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseImmunohistochemistryHead and neck squamous-cell carcinomastomatognathic diseasesInfectious DiseasesReal-time polymerase chain reactionOncologyImmunohistochemistryOSCCbusinessResearch ArticleIHCInfectious Agents and Cancer
researchProduct